Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on October 23, 2006. The filing discloses the entry into a material definitive agreement regarding the termination of employment for a senior executive.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of an executive separation agreement.
Material Changes
The primary material change is the agreement to terminate the employment of Vincent J. Miles, Ph.D., Senior Vice President of Business Development. The agreement outlines a transition from full-time to part-time employment and specific compensation terms.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or general management commentary. It details the specific terms of the separation:
- Employment Status: Dr. Miles remains a full-time employee through December 31, 2006, and transitions to part-time status from January 1, 2007, until August 1, 2007.
- Compensation: He will receive his current base salary through December 31, 2006. From January 1, 2007, he will receive 50% of his current base salary ($5,420 per regular semi-monthly period).
- Termination Protection: If the Company terminates his employment without cause prior to August 1, 2007, he is entitled to receive his applicable salary through that date.
- Benefits: Medical and dental coverage under group plans cease during part-time employment, though the Company will reimburse the difference in premiums if he elects COBRA coverage.
- Lump-Sum Payment: A lump-sum cash payment is calculated as $1,122.91 multiplied by the number of full weeks he remains continuously employed as a 50% part-time employee between January 1, 2007, and August 1, 2007. This full amount is guaranteed if terminated without cause.
- Release: In consideration for these payments, Dr. Miles agreed to release the Company from all claims.
Investor Verification Checklist
- Verify the exact date of Dr. Miles' departure and whether the part-time transition period was completed as scheduled.
- Confirm the total cash outflow associated with the lump-sum payment and salary continuation.
- Assess the impact of losing the Senior Vice President of Business Development on the company's pipeline and partnership strategy.
- Review subsequent filings to determine if a replacement for this role was identified.